• 1
    Cominelli S, Raguso CA, Karsegard L et al. Weight-losing HIV-infected patients on recombinant human growth hormone for 12 wk: a national study. Nutrition 2002; 18:583586.
  • 2
    Napolitano LA, Lo JC, Gotway MB et al. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002; 16:11031111.
  • 3
    Moyle GJ, Daar ES, Gertner JM et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35:367375.
  • 4
    Pires A, Pido-Lopez J, Moyle G, Gazzard B, Gotch F, Imami N. Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy. Antivir Ther 2004; 9:6775.
  • 5
    Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imami N. Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. J Immune Based Ther Vaccines 2008; 6:7.
  • 6
    Napolitano LA, Schmidt D, Gotway MB et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 2008; 118:10851098.
  • 7
    Lo J, You SM, Canavan B et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008; 300:509519.
  • 8
    Grunfeld C, Thompson M, Brown SJ et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12-week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45:286297.
  • 9
    Hansen BR, Kolte L, Haugaard SB et al. Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS 2009; 23:21232131.
  • 10
    Smith K, Zheng L, Bosch R et al. Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. AIDS Res Hum Retroviruses 2010; 26:425432.
  • 11
    Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011; 32:131137.
  • 12
    Kaufmann GR, Elzi L, Weber R et al. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 2011; 25:441451.
  • 13
    Welniak LA, Sun R, Murphy WJ. The role of growth hormone in T-cell development and reconstitution. J Leukoc Biol 2002; 71:381387.
  • 14
    Rietschel P, Hadigan C, Corcoran C et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86:504510.
  • 15
    Vigano A, Mora S, Brambilla P et al. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS 2003; 17:14351441.
  • 16
    Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther 2007; 29:22692288.
  • 17
    Sivakumar T, Mechanic O, Fehmie DA, Paul B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med 2011; 12:453462.
  • 18
    Goodier MR, Imami N, Moyle G, Gazzard B, Gotch F. Loss of the CD56hiCD16 natural killer (NK) cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone. Clin Exp Immunol 2003; 134:470476.
  • 19
    Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case–control study. Lancet 2003; 361:726735.
  • 20
    Imami N, Hardy GA, Nelson MR et al. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin Exp Immunol 1999; 118:7886.
  • 21
    Hardy GA, Imami N, Nelson MR et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vaccines 2007; 5:6.
  • 22
    Hunt PW, Deeks SG. Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J Infect Dis 2006; 194:16321634.
  • 23
    Hazenberg MD, Otto SA, van Benthem BH et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:18811888.
  • 24
    Bartovska Z, Beran O, Rozsypal H, Holub M. Antiretroviral treatment of HIV infection does not influence HIV-specific immunity but has an impact on non-specific immune activation. Curr HIV Res 2011; 9:8894.
  • 25
    Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471484.
  • 26
    Downey JS, Imami N. T-cell dysfunction in HIV-1 infection: targeting the inhibitors. HIV Ther 2010; 4:8399.
  • 27
    Betts MR, Ambrozak DR, Douek DC et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:1198311991.
  • 28
    Maecker HT, Dunn HS, Suni MA et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001; 255:2740.
  • 29
    Stanley TL, Grinspoon SK. GH/GHRH axis in HIV lipodystrophy. Pituitary 2009; 12:143152.
  • 30
    Franco JM, Rubio A, Martinez-Moya M et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99:37023706.
  • 31
    Kotler DP, Muurahainen N, Grunfeld C et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:239252.
  • 32
    Lo J, You SM, Liebau J, Lee H, Grinspoon S. Effects of low-dose growth hormone withdrawal in patients with HIV. JAMA 2010; 304:272274.
  • 33
    Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev 1997; 18:157179.
  • 34
    Rao MN, Mulligan K, Tai V et al. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 2010; 95:43614366.
  • 35
    Falutz J, Mamputu JC, Potvin D et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010; 95:42914304.
  • 36
    Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:13041307.
  • 37
    Deeks SG, Autran B, Berkhout B et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607614.
  • 38
    Rosenfeld RG, Cohen P, Robison LL et al. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab 2012; 97:6872.